HTB

UK named-patient access to tipranavir

3 February 2004. Related: Antiretrovirals.

The named-patient access to tipranavir that started in Autumn 2003 is still continuing. Entry criteria for this limited programme include:

  • Require tipranavir to construct a viable combination of anti-retroviral agents for therapy based on current treatment guidelines and the patient’s previous anti-retroviral history.
  • 18 years of age or over, or is >/=13 years of age, with a total body weight >/= 50kg.
  • CD4+ count less than 50 cells/mm3
  • HIV RNA greater than 10,000 copies/ml

Patients taking or intending to take additional protease inhibitors with tipranavir and ritonavir are currently not eligible for named patient supply.

Clinicians should contact Sarah Jones in the medical division of Boehringer Ingelheim on 01344 742539 or 07776 483808 for further information regarding the programme.

Links to other websites are current at date of posting but not maintained.